Table 6.
Characteristics of the study sample of patients with and without LVH
| |
LVH |
P values |
|
|---|---|---|---|
| Patient Group with LVH | Patient group without LVH | ||
| Age (years) |
56.8 ± 12.1 |
66.3 ± 10.6 |
0.001 |
| Sex (male/female) |
49/31 |
78/42 |
0.589 |
| Family history of hypertension (yes/no) |
48/32 |
65/55 |
0.415 |
| Family history of stroke (yes/no) |
15/65 |
24/96 |
0.827 |
| Smokers (yes/ex/no) |
17/18/45 |
18/24/78 |
0.404 |
| Diabetes (yes/no) |
2/78 |
18/102 |
0.004 |
| Diastolic BP (mmHg) |
73.8 ± 12.1 |
76.8 ± 11.8 |
0.094 |
| Systolic BP (mmHg) |
126.1 ± 25.3 |
137.9 ± 19.4 |
0.001 |
| Pulse pressure (mmHg) |
52.3 ± 18.0 |
61.1 ± 16.8 |
0.001 |
| Fasting blood glucose (mmHg) |
99.8 ± 23.6 |
104.7 ± 24.3 |
0.161 |
| Total Cholesterol (mg/dl) |
191.0 ± 38.6 |
182.3 ± 41.7 |
0.132 |
| BMI (kg/m2) |
27.2 ± 4.3 |
28.0 ± 4.8 |
0.235 |
| Beta-blockers (yes/no) |
31/49 |
36/84 |
0.199 |
| Alphabeta-blockers (yes/no) |
7/73 |
14/106 |
0.510 |
| Alpha-blockers (yes/no) |
5/75 |
11/109 |
0.456 |
| Diuretics (yes/no) |
25/55 |
62/58 |
0.004 |
| ACE inhibitor (yes/no) |
25/55 |
50/70 |
0.136 |
| Dihydropyridine (yes/no) |
17/63 |
35/85 |
0.211 |
| eGFR (mL/min/1.73 m2) |
79.9 ± 17.9 |
75.1 ± 19.5 |
0.071 |
| Kidney Involvement (1/2 /3) |
24/44/12 |
24/75/21 |
0.268 |
| IMT (mm) |
1.82 ± 0.93 |
2.52 ± 1.82 |
<0.001 |
| Vascular abnormalities (no/ thickening/plaque) |
20/11/49 |
6/11/103 |
<0.001 |
| LVMi g/m2 | 105.0 ± 13.8 | 147.5 ± 27.3 | <0.001 |
Data are expressed as mean and standard deviation for continuous variables (i.e. age) and as number of patients per each group for categorical variable (i.e. gender).
The p-values refer to t-test for continuous variables and χ2 for categorical variables.